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Membrane Type I Matrix Metalloproteinase
Usurps Tumor Growth Control Imposed
by the Three-Dimensional Extracellular Matrix
of type I collagen or crosslinked fibrin (Hanahan and
Weinberg, 2000; Hiraoka et al., 1998; Liotta and Kohn,
2001; Chambers et al., 2002). However, despite the fact
that the ECM is imbued with potent growth-suppressive
properties (Nishiyama et al., 1989; Koyama et al., 1996;
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Henriet et al., 2000), cancer cells can proliferate at accel-University of Michigan Comprehensive
erated rates within this 3D environment by circum-Cancer Center
venting antigrowth signals (Hanahan and Weinberg,2Division of Hematology/Oncology
2000; Chambers et al., 2002).Department of Pediatrics
Strategies used by cancer cells to grow rapidly withinUniversity of Michigan
a 3D ECM remain undefined. A potential role for protein-Ann Arbor, Michigan 48109
ases in regulating tumor cell proliferation in vivo has3 Department of Radiation Oncology
been posited on the basis of the growth-suppressiveNew York University School of Medicine
activities displayed by broad spectrum inhibitors di-New York, New York 10016
rected against enzymes belonging to the serine protein-
ases, cysteine proteinases, matrix metalloproteinase
(MMP), or adamalysin gene families (Hidalgo and Eck-Summary
hardt, 2001; Coussens et al., 2002). These proteinases
cleave a wide variety of substrates that could affect cellCancer cells are able to proliferate at accelerated rates
growth including cell adhesion molecules, membrane-within the confines of a three-dimensional (3D) extra-
anchored as well as soluble growth factors, growth fac-cellular matrix (ECM) that is rich in type I collagen.
tor receptors, chemokines, and ECM macromoleculesThe mechanisms used by tumor cells to circumvent
(Brinckerhoff and Matrisian, 2002; Coussens et al., 2002;endogenous antigrowth signals have yet to be clearly
Egeblad and Werb, 2002). However, antiproteinases al-defined. We find that the matrix metalloproteinase,
most uniformly exert more significant effects on tumorMT1-MMP, confers tumor cells with a distinct 3D
cell growth in vivo than in vitro (Hidalgo and Eckhardt,growth advantage in vitro and in vivo. The replicative
2001; Coussens et al., 2002). As such, current opinionadvantage conferred by MT1-MMP requires pericellu-
favors the possibility that proteinases indirectly controllar proteolysis of the ECM, as proliferation is fully sup-
the proliferative activity of cancer cells by either cleavingpressed when tumor cells are suspended in 3D gels
targets peculiar to the in vivo environment (e.g., matrix-of protease-resistant collagen. In the absence of pro-
associated growth factors) or by affecting the angio-teolysis, tumor cells embedded in physiologically rele-
genic response necessary for supporting tumor expan-vant ECM matrices are trapped in a compact, spherical
sion (Hidalgo and Eckhardt, 2001; Coussens et al., 2002;configuration and unable to undergo changes in cell
Egeblad and Werb, 2002).shape or cytoskeletal reorganization required for 3D
To date, the consensus that proteinases do not regu-growth. These observations identify MT1-MMP as a
late tumor cell growth directly has been based largelytumor-derived growth factor that regulates prolifera-
on in vitro model systems wherein cancer cell behaviortion by controlling cell geometry within the confines
is classically assessed in a 2D environment atop eitherof the 3D ECM.
a plastic substratum or a planar coat of ECM macromol-
ecules. As cell behavior is critically affected by the physi-
cal presentation of the surrounding ECM (Cukierman et
Introduction
al., 2001, 2002; Walpita and Hay, 2002), we considered
the possibility that proliferative responses of matrix-
During the initial phases of the neoplastic process, tu- embedded cancer cells are controlled differentially un-
morigenic epithelial cells proliferate at accelerated rates der 3D conditions more relevant to the in vivo milieu
in the two-dimensional (2D) environment that exists atop encountered by tissue-invasive cells. Herein, we demon-
the underlying basement membrane (Hanahan and strate that the membrane-anchored matrix metallopro-
Weinberg, 2000; Liotta and Kohn, 2001; Chambers et teinase, MT1-MMP, confers tumor cells with a 3D growth
al., 2002). As transformation progresses, cancer cells advantage by directly driving proliferative responses
acquire the ability to penetrate the basement membrane within the confines of physiologically relevant ECM ma-
and infiltrate the subjacent stromal matrix (Hanahan and trices in vitro or in vivo. MT1-MMP-enhanced growth is
Weinberg, 2000; Liotta and Kohn, 2001; Chambers et reversed completely by either suspending cancer cells
al., 2002). Coincident with the expression of the tissue- in a 3D matrix constructed from type I collagen fibrils
invasive phenotype, the tumor cell adapts itself for an harboring knockin mutations surrounding the major
abrupt transition in growth environments. No longer con- MMP cleavage site in the triple helix or by blocking
fined to the planar surface of the extracellular matrix fibrinolysis. In the absence of ECM proteolysis, matrix-
(ECM), the invading cells are forced to proliferate within embedded tumor cells are locked in a compact configu-
a dense three-dimensional (3D) matrix composed largely ration and are unable to alter cell geometry in a fashion
consistent with a proliferative response. These findings
identify MT1-MMP as collagenolytic/fibrinolytic growth*Correspondence: sjweiss@umich.edu
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Figure 1. MMP Regulation of Cell Proliferation
(A) SCC-1, Panc-1, or HT-1080 cells were seeded at an initial density of 5  104 cells/well atop (2D) or within (3D) type I collagen gels in the
absence or presence of TIMP-2 (5 g/ml) or TIMP-1 (12.5 g/ml) and cultured for 8 days, at which time cell number was determined.
(B) Control or MMP-transfected MDCK cells were cultured atop collagen gels for 8 days and cell number determined in the absence or
presence of TIMP-2 (5 g/ml; top). Under 3D growth conditions, MT1-MMP-transfected cells proliferated at a significantly faster rate than
control cells (middle; p  .001) via a TIMP-2-, but not TIMP-1-, sensitive process. Results are expressed as the mean  1 SEM for triplicate
cultures.
(C) Control, MMP-1-, MMP-13-, MMP-2-, or MT1-MMP-transfected MDCK cells were cultured within type I collagen gels in the absence or
presence of TIMP-2 (5 g/ml) for 8 days (100). Insets show subconfluent cells on 2D collagen gels after 5 days.
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factor that provides cancer cells with the ability to accel- inhibitor of secreted MMPs that only inefficiently regu-
lates MT1-MMP activity (Hotary et al., 2002), did noterate proliferative responses by defeating the growth-
suppressive signals embedded within the 3D ECM. affect the accelerated growth rate of MT1-MMP-trans-
fected MDCK clones or wild-type cancer cells (Figures
1A–1C).Results
MT1-MMP as a Direct-Acting Growth PromoterMMP-Dependent Regulation of 3D Growth
MMPs are normally synthesized and secreted as inac-Under planar growth conditions atop the surface of
tive proenzymes, whereas the MT1-MMP prodomain istype I collagen gels, squamous carcinoma cells (SCC-1),
encrypted with a proprotein convertase recognition mo-pancreatic carcinoma cells (Panc-1), or fibrosarcoma
tif that allows the zymogen to undergo intracellular pro-cells (HT-1080) proliferate rapidly relative to tumor cells
cessing to its active form prior to its display at the cellembedded within the type I collagen matrix where growth
surface (Yana and Weiss, 2000; Brinckerhoff and Matri-decreases by70% (Figure 1A). Further, whereas neither
sian, 2002). To rule out the possibility that MT1-MMPserine- (aprotinin, soybean trypsin inhibitor), cysteine-
controlled cell proliferation only as a function of its effi-(E-64), aspartyl- (pepstatin), nor matrix metallo-protein-
cient processing to an active proteinase, chimeric formsase inhibitors affect tumor cell growth under 2D condi-
of MMP-1, MMP-2, and MMP-13 (MMP-1RXKR, MMP-2RXKR,tions (Figure 1B and data not shown), 3D proliferation
MMP-13RXKR) were expressed wherein an Arg-X-Arg-X-of SCC-1, Panc-1, and HT-1080 cells is inhibited50%–
Lys-Arg (RXRXKR) motif recognized by proprotein con-80% by the MMP inhibitor, TIMP-2 (Figure 1B). Similar
vertases was inserted between the propeptide and cata-results were obtained with the synthetic MMP inhibitor,
lytic domains of each of the respective MMPs (Pei andBB-94 (data not shown). Hence, within a growth-sup-
Weiss, 1995). Under these conditions, each of the RXKRpressive, 3D matrix of type I collagen, tumor cell prolifer-
constructs is secreted as the active proteinase in stablyation is controlled by an MMP-dependent process.
transfected clones (Figure 2A). However, none of theTo identify the TIMP-2-sensitive proteinase(s) that
three active MMP chimeras accelerates growth undercontrol 3D growth, a nontumorigenic cell line known to
3D conditions relative to control transfected clones (Fig-express low levels of a limited repertoire of MMPs, i.e.,
ure 2B and data not shown).MDCK cells (Hotary et al., 2000), was engineered to
Following intracellular processing, the mature, activestably express a series of MMPs previously associated
form of MT1-MMP can catalyze the activation of eitherwith tumor growth in vivo (Hidalgo and Eckhardt, 2001;
the MMP-2 or MMP-13 zymogens (Brinckerhoff and Ma-Coussens et al., 2002; Egeblad and Werb, 2002). As
trisian, 2002), leaving open the possibility that MT1-observed with the tumor cell lines, the proliferative activ-
MMP-dependent growth acceleration occurs becauseity of control MDCK clones is suppressed strongly when
of its ability to activate MMP-2 or MMP-13. Thoughshifted from a 2D to 3D growth environment (Figure 1B).
MDCK cells secrete virtually undetectable levels ofHowever, consistent with the limited potential of wild-
MMP-2, the serum-supplemented media contains sig-type MDCK cells to express MMPs, TIMP-2 only mod-
nificant levels of the proenzyme (Hiraoka et al., 1998;estly affects 3D growth of control clones (Figure 1B).
Hotary et al., 2000). Nonetheless, the growth rate ofDespite a paucity of endogenous MMPs, the replicative
the MT1-MMP-transfectants remains robust in MMP-2-response of MDCK stable clones is not enhanced under
depleted media (Figure 2C). Further, the ability of MMP-22D or 3D growth conditions by overexpressing the se-
or MMP-13 to augment MT1-MMP-dependent growthcreted MMPs, MMP-1 (collagenase-1), MMP-13 (collagen-
in cis or trans was also examined by culturing MT1-ase-3), or MMP-2 (gelatinase A) (Figure 1B). Similarly, sta-
MMP transfectants with MDCK clones overexpressingble transfectants overexpressing MMP-3 (stromelysin-1),
either MMP-2 or MMP-13. In these coculture experi-MMP-7 (matrilysin), MMP-9 (gelatinase B), or MMP-11
ments, neither the size nor the morphology of the 3D(stromelysin-3) proliferate at normal rates under 2D condi-
spheroids generated by the MT1-MMP transfectants istions (100%  5%, 98%  2%, 88%  3%, and 94% 
altered in the presence of the MMP-2 or MMP-13 overex-5% of control transfected cells, respectively) or 3D con-
pressing clones (Figure 2D). Taken together, these dataditions (96%  12%, 107%  19%, 112%  21%, or
imply that MT1-MMP regulates 3D growth directly.111%  25% of control transfected cells, respectively;
n  3). By contrast, in MDCK clones expressing the
membrane-anchored MMP, MT1-MMP, cell number in- MT1-MMP Confers Tumor Cells with a Growth
Advantage In Vitro and In Vivocreases at an accelerated rate under 3D, but not 2D,
growth conditions (Figure 1B). Changes in 3D cell growth While MT1-MMP conferred a growth advantage to a
nontumorigenic cell line, neoplastic tumor cell lines mayrates are also accompanied by marked changes in the
morphology of the embedded cysts (Figure 1C). TIMP-2, employ alternate strategies for maximizing proliferation
within the 3D environment (Hanahan and Weinberg,an efficient MT1-MMP inhibitor (Hotary et al., 2000,
2002), suppresses the growth rate of the MT1-MMP 2000; Chambers et al., 2002). Consequently, the ability of
MT1-MMP overexpression to promote tumor cell growthtransfectants to control levels under 3D growth condi-
tions and completely reverses the aberrant cyst mor- was examined in SCC-1 cells as well as an MT1-MMP-
deficient, breast carcinoma cell line (MCF-7 cells;phology (Figures 1B and 1C). Likewise, MDCK clones
expressing a catalytically inactive form of MT1-MMP Sounni et al., 2002). As shown in Figure 3, control trans-
fected SCC-1 cells proliferate as loose aggregates in(Yana and Weiss, 2000) did not stimulate proliferation
relative to control transfected clones (i.e., 109%  3% 3D collagen gels (panels A–C). By contrast, the growth
rate of MT1-MMP-transfected SCC-1 cells increases byof control transfected cells; n  3). TIMP-1, a potent
Cell
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Figure 2. MT1-MMP Enhancement of Cell Growth
(A) Processing of RXKR-inserted MMPs as assessed by Western blotting (MMP-1 and MMP-13) or gelatin zymography (MMP-2). Open and
closed arrows indicate the pro and active forms of the enzymes, respectively, while brackets enclose glycosylated and nonglycosylated forms.
(B) MDCK cells were stably transfected with the empty vector, RXKR-inserted MMP-1 (MMP1RXKR), MMP-13 (MMP13RXKR), MMP-2 (MMP2RXKR),
or wild-type MT1-MMP and cultured for 8 days within collagen gels in the absence or presence of TIMP-2 (5 g/ml).
(C) Proliferative response of control or MT1-MMP expressing cells after 8 days in gelatinase-depleted serum. Expressed as the mean  1
SEM for triplicate cultures.
(D) DiI-labeled (red) MT1-MMP transfectants (2.5  104) were cocultured with 2.5  104 unlabeled control, MMP-2-, or MMP-13-transfected
cells in 3D collagen for 8 days. Cultures were DAPI stained (blue), and red and blue digital images of the same field were collected and
merged. In merged images, MT1-MMP-expressing cells appear pink/red while control, MMP-2-, or MMP-13-transfected cells appear blue.
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Figure 3. Regulation of SCC-1 Proliferation by MT1-MMP in 3D Culture
(A) Control SCC-1 or SCC-1 clones expressing MT1-MMP, soluble MT1-MMP (MT1-MMP), or cytosolic tail-deleted MT1-MMP (MT1-MMPct)
were cultured in 3D collagen for 8 days in the absence or presence of TIMP-2 (5 g/ml). Immunoblots show representative expression levels
of each construct. MT1-MMP levels in cells transfected with the wild-type enzyme is approximately 50% that detected in HT-1080 cells (data
not shown). Open and closed arrows indicate pro and active forms of MT1-MMP, respectively.
(B) Transmission electron micrographs of control and MT1-MMP-transfected SCC-1 cells growing as loose aggregates for 8 days in 3D
collagen (500).
(C) Growth of control, MT1-MMP-, MT1-MMP-, and MT1-MMPct-transfected SCC-1 cells in 3D culture in the absence or presence of TIMP-2
(5 g/ml) expressed as the mean  1 SEM for triplicate cultures.
(D) BrdU uptake in control or MT1-MMP-transfected MDCK (photos and open bars) and SCC-1 (closed bars) cells was monitored in the
absence or presence of TIMP-2 (5 g/ml) in 3D cultures. The percentage of BrdU-positive cells (green) among all cells (red) per longitudinal
section was determined after 8 days in culture. Bar graphs show representative counts for one complete section.
(E) Relative expression levels for cyclin D3 and CDK4 expression as well as cyclin D3 kinase activity was determined in control and MT1-
MMP-transfected SCC-1 cells after 8 days in 2D or 3D collagen culture. Results are representative of three experiments performed.
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approximately 2.5-fold under 3D conditions, coincident relates with the level of MT1-MMP expression (data not
with a decrease in the density of cell packing within shown) and is independent of apoptotic indices (Figure
the tumor cell aggregates (Figures 3A–3C). Consistent 4). Contrary to recent reports (Sounni et al., 2002; Deryu-
with their MT1-MMP-deficient status, control clones of gina et al., 2002), VEGF expression by MT1-MMP
MCF-7 breast carcinoma cells only marginally increase transfectants was not increased in vivo or in vitro (data
in cell number over an 8 day culture period under 3D not shown).
growth conditions (i.e., from 50  103 to 64  6  103; In preliminary studies designed to assess MT1-MMP
n  3). However, stable expression of MT1-MMP in structure/function relationships underlying growth en-
MCF-7 cells leads to a 4.2  0.3-fold increase in cell hancement in vivo, the cytosolic tail-deleted form of
growth (i.e., to 25.2 2.1 104 cells; n 3). Significantly, MT1-MMP increased tumor mass similarly to wild-type
increased growth rate reflects an increase in the prolifer- MT1-MMP (i.e., mean tumor mass in 5 mice injected at
ative index for MT1-MMP-transfected cells, since apop- two sites with a control transfected clone was 227  52
totic rates are not affected by MT1-MMP expression mg versus 997  115 mg for MT1-MMPct). By contrast,
(Figures 3D and data not shown). Likewise, the ability 2 of 3 clones overexpressing soluble MT1-MMP grew
of TIMP-2 to reverse the MT1-MMP-dependent growth at rates indistinguishable from the control clone (i.e.,
advantage represents a decrease in the proliferative in- 237  31 mg and 225  50 mg). Taken together, these
dex alone (Figures 3C and 3D) with no change in apopto- data suggest that membrane-anchored MT1-MMP con-
sis as assessed by TUNEL (data not shown). fers a growth advantage in vitro as well as in vivo by
Given that MT1-MMP-dependent effects are limited stimulating cell proliferation.
to changes in proliferative indices, cell cycle changes
associated with the transition of cancer cells from 2D to MT1-MMP-Dependent Type I Collagenolysis
3D growth environments were assessed. While neither Is Required for 3D Growth
cyclin D1, D3, A, or E nor CDK2, CDK4, or CDK6 expres- MMPs can alter cell behavior by proteolyzing a range
sion are affected by MT1-MMP expression in cells cul- of nonextracellular matrix targets (Coussens et al., 2002;
tured atop or within collagen gels, cyclin D3 kinase activ- Egeblad and Werb, 2002). Though MT1-MMP might reg-
ity is markedly upregulated in MT1-MMP-transfected ulate proliferative responses by targeting cell-derived
cells under 3D, but not 2D, growth conditions (Figure 3E). factors independent of the surrounding matrix, MT1-
Changes in cyclin D3 kinase activities were confirmed in MMP does not confer a growth advantage when cells
additional SCC-1 clones and could be reversed com- are suspended in a 3D gel of either soft agar (Figure 5A)
pletely by TIMP-2 (data not shown). Under 2D growth or in Matrigel, a matrix rich in laminin and type IV
conditions, neither proliferation nor apoptosis is altered collagen (data not shown). As the MT1-MMP-dependent
by overexpressing MT1-MMP in SCC-1 or MCF-7 cells. proliferative response is dependent on the 3D collagen
Recent studies suggest that the cytosolic tail and matrix, these observations are consistent with the gen-
transmembrane domains of MT1-MMP play a major role eration of a collagen-derived growth enhancer or pro-
in regulating its activity and function (Seiki, 2002). As teolytic inactivation of a diffusible growth suppressor.
the processing of MT1-MMP to its catalytically active
However, the latter hypothesis is made less likely given
form is unaffected by deleting the cytosolic tail or trans-
that MT1-MMP-transfected cells cocultured in close
membrane domain (Hiraoka et al., 1998; Yana and Weiss,
proximity to control transfectants in 3D collagen gels
2000; Hotary et al., 2000, 2002), we sought to determine
do not affect the proliferation rate of the control cloneswhether the growth-promoting activity of MT1-MMP is
(Figure 5B).dependent on either of these domains. Hence, SCC-1
Alternatively, candidates for collagen-derived growthcell lines were generated that expressed membrane-
enhancers that may account for MT1-MMP-dependentanchored MT1-MMP with either the cytosolic domain
phenotype include gelatin, a known v3 ligand that canor the transmembrane domain deleted (MT1-MMPct or
affect cell growth (Petitclerc et al., 1999; Xu et al., 2001).MT1-MMP, respectively). While tail-deleted MT1-MMP
Gelatin is generated from triple-helical collagen follow-confers a similar growth advantage to transfected carci-
ing its proteolysis by MT1-MMP at a single site to gener-noma cells, the soluble, transmembrane-deleted form of
ate two fragments that spontaneously undergo thermalMT1-MMP does not display growth-enhancing activity
denaturation at 37	C (Ohuchi et al., 1997). However,(Figures 3A and 3C). Thus, only the membrane-anchored
while pericellular gelatin staining is detected surroundingdisplay of MT1-MMP at the cell surface is a necessary
MT1-MMP-transfected cells in the absence, but not therequirement for promoting tumor cell growth.
presence, of TIMP-2 (Figure 5C), exogenous gelatin in-In vivo, type I collagen is the major extracellular matrix
corporated into collagen gels fails to stimulate thein the dermis where its concentration is estimated at 30
growth of control or MT1-MMP-transfected cells in themg/ml (Hay, 1991). To determine whether MT1-MMP
presence or absence of TIMP-2 (Figure 5D). Likewise,regulates tumor cell behavior in this more stringent envi-
growth was unaffected by monoclonal antibodies (LM609ronment, tumor mass, proliferation, and apoptosis were
or HU177), which interfere specifically with gelatin bind-determined in a mouse model following the intradermal
ing to cell surface integrins (Figure 5E; Petitclerc et al.,injection of wild-type SCC-1 cells, control transfectants,
1999; Xu et al., 2001).or MT1-MMP-transfected clones expressing high, inter-
While the formation of collagen degradation productsmediate, or low levels of the proteinase (clones MT1-
could not be directly implicated in MT1-MMP-depen-MMP-1c, MT1-MMP-3c, and MT1-MMP-6, respectively).
dent proliferative responses, the growth-suppressiveAs shown in Figure 4, the tumor mass and proliferative
properties of 3D collagen itself might prove sensitive toindex of MT1-MMP transfectants increases at acceler-
ated rates in vivo. The growth-promoting phenotype cor- proteolytic attack. Hence, tumor cell growth was com-
MT1-MMP Regulates 3D Tumor Growth
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Figure 4. SCC-1 Tumor Growth in Nude Mice
(A) Tumors generated in the flanks of nude mice are shown 2 weeks after the subcutaneous injection of 5  106 wild-type, control, or MT1-
MMP-transfected SCC-1 cells (clone MT1-MMP-1c). Chart shows individual tumor masses (10 for each clone) with the mean indicated by a
red bar. The levels of MT1-MMP in clones 3c and 6 were approximately 60% and 25%, respectively, of that expressed in clone 1c.
(B) Proliferative and apoptotic indices were determined in tumor sections from nude mice inoculated with control or MT1-MMP-1c-transfected
SCC-1 cells by PCNA staining and TUNEL, respectively. Propidium iodide counterstaining (red) was used to determine total cell numbers.
pared in collagen gels isolated from wild-type mice and suspended in wild-type collagen supplemented with
TIMP-2 (Figures 5F and 5G). Whereas TIMP-2 signifi-transgenic mice harboring a knockin mutation that dis-
rupts the site of collagenolytic attack (i.e., r/r collagen; cantly inhibits the growth of MT1-MMP-transfected cells
in wild-type collagen, their growth rate remains unper-Liu et al., 1995). Significantly, the growth of MT1-MMP-
transfected cells in r/r collagen is suppressed to levels turbed when r/r gels are supplemented with TIMP-2 (Fig-
ure 5B). Further, when suspended in r/r collagen, Panc-1similar to those displayed by control transfected cells
Cell
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Figure 5. Characterization of the MT1-MMP-Mediated Growth Enhancement
(A) Control and MT1-MMP-transfected MDCK or SCC-1 cells (5  104) were cultured in 0.5% agar for 8 days. Results are expressed as the
mean number of colonies  1 SEM in triplicate cultures.
(B) MT1-MMP-transfected MDCK cells (2.5  104) were DiI-labeled (red) and cocultured with DiO-labeled (green) control (2.5  104) MDCK
cells as illustrated (top). After 8 days, red and green digital images of the same field were collected.
(C) MT1-MMP transfectants cultured in 3D collagen for 8 days displayed an enhanced ability to generate collagen degradation products in
the pericellular milieu relative to control-transfected cells. Degraded collagen (detected by mAb HUI77) appears as punctuate green staining
around propidium iodide-labeled cells (red). In the presence of TIMP-2 (5 g/ml), staining for degraded collagen is reduced to background
levels.
(D and E) Control and MT1-MMP-transfected SCC-1 cells were cultured for 8 days in collagen gels impregnated with 1% gelatin or 0.5%
MT1-MMP-generated collagen fragments in the absence or presence of TIMP-2 (5 g/ml; D) or with mAb LM609 (20 g/ml) or HUI77 (100
g/ml) (E). Results are expressed as the mean percent of control cell numbers  1 SEM of triplicate cultures.
(F) Control or MT1-MMP-transfected SCC-1 cells were buried in wild-type or r/r mouse collagen for 8 days and morphology assessed.
(G and H) Cell numbers were determined for control and MT1-MMP-transfected SCC-1 cells (7.5  103) cultured within (3D) (G) or atop (2D)
(H) collagen gels isolated from wild-type or r/r mice for 8 or 5 days, respectively, in the absence or presence of TIMP-2 (5 g/ml). Results are
expressed as the mean cell number  1 SEM for triplicate cultures.
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and HT-1080 as well as MT1-MMP-transfected MCF-7 to TIMP-2-treated cells where the actin network is con-
fined to a thin, cortical shell (Figure 6E). By contrast,cells all display a reduced proliferative activity similar
to that observed in 3D gels of wild-type collagen supple- MT1-MMP-deficient MCF-7 cells suspended in 3D gels
are locked into spheres that can only undergo shapemented with TIMP-2 (i.e., after 8 days in culture in wild-
type versus r/r collagen, the proliferation of Panc-1 cells change and rearrange their actin cytoskeleton following
expression of MT1-MMP in the absence, but not thedecreased from 44.4  2.0  104 to 13.2  8  104, HT-
1080 cell number decreased from 67.8  4.4  104 to presence, of TIMP-2 (Figure 6E). While cell spreading
and cytoskeletal restructuring is unaffected by MT1-6.7  4.0  104, and the proliferation of MT1-MMP-
transfected MCF-7 cells decreased from 25.2  104 to MMP under 2D growth conditions (data not shown), the
percentage of MT1-MMP-transfected SCC-1 cells un-3.5  5.0  104; n  3). In contrast to the inhibitory
effects exerted by r/r collagen under 3D growth condi- dergoing shape change in 3D collagen, fibrin, or skin
(79%, 91%, and 57%, respectively) is decreased to 11%,tions, proliferation of control transfected or MT1-MMP-
transfected carcinoma cells is not altered under 2D 4%, and 14% in the presence of TIMP-2. Likewise, the
number of MCF-7 cells able to undergo a 3D shapegrowth conditions atop r/r collagen gels (Figure 5H).
change increases from 6% in collagen gels and 5% in
fibrin gels to 61% and 52%, respectively, following MT1-Geometric Control of 3D Tumor Cell Proliferation
MMP expression (n  2). As expected, 3D growth ofIs Regulated by MT1-MMP
cancer cells is inhibited dramatically when the actin net-The ability of 3D collagen to regulate cell proliferation
work is disrupted with 1 g/ml cytochalasin D (e.g.,could reflect integrin- or discoidin receptor-mediated
the growth of control and MT1-MMP-expressing SCC-1signaling (e.g., Cukierman et al., 2002) or alternatively,
cells decreases from 228  16  103 and 642  48 growth suppression consequent to enmeshing the tu-
103, respectively, to 20  4  103 and 24  2  103 cellsmor cells in a physical cage that prevents the well-
during 8 days in culture) (Ingber, 2003). Thus, within thecharacterized changes in cell geometry and cytoskeletal
confines of the 3D ECM, MT1-MMP-dependent pericel-rearrangements necessary to drive a proliferative re-
lular proteolysis regulates the critical changes in cellsponse (e.g., Chen et al., 1997; Ingber, 2003; Tan et al.,
geometry that drive the proliferative response.2003). If collagen fibers act as a 3D growth regulator by
constraining tumor cell shape, then a structurally dis-
tinct fibrillar network should exert similar, if not identical, Discussion
effects on tumor cell geometry and growth. Fibrin, like
type I collagen, enmeshes cancer cells in a dense, cross- As epithelial-derived cancer cells engage gene pro-
grams necessary to promote invasion from primary siteslinked fibrillar network in vivo that can be proteolyzed
by MT1-MMP (Hiraoka et al., 1998; Hotary et al., 2002). into the underlying stroma, they must adapt to the new
growth conditions dictated by life within a dense, 3DSignificantly, 3D fibrin gels suppressed cell growth com-
parably to collagen gels (e.g., the growth of wild-type meshwork of ECM macromolecules (Liotta and Kohn,
2001; Chambers et al., 2002). Under normal circum-MDCK cells or SCC-1 cells in 3D fibrin is depressed
by 79% and 80%, respectively, relative to 2D growth stances, the type I collagen-rich interstitial matrix has been
thought to effectively regulate cell growth by either ligatingconditions; n 2). Further, as in the case of 3D collagen
gels, only MT1-MMP confers MDCK transfectants with collagen-specific receptors (Cukierman et al., 2002) or se-
questering ECM bound growth factors (Egeblad anda growth advantage in 3D fibrin gels (a 2.2  0.2-fold
increase in cell number relative to control transfectants; Werb, 2002). Yet, within the same 3D ECM, tissue-inva-
sive cancer cells almost immediately begin to proliferaten  4) while likewise stimulating SCC-1 and MCF-7 cell
proliferation in a TIMP-2-sensitive fashion (Figures 6A at accelerated rates (Chambers et al., 2002). Thus, in
the earliest stages of postinvasive growth, cancer cellsand 6B).
In the presence of serum-derived mitogens, anchor- are able to replicate in an autonomous fashion until the
metabolic requirements of the tumor mass can no longerage-dependent growth atop planar substrates will not
proceed through the cell cycle restriction point into be met by simple diffusion and an angiogenic switch is
activated in order to recruit new blood vessels (HanahanS phase unless adherent cells can spread, engage con-
tractile machinery, and rearrange their actin cytoskele- and Weinberg, 2000).
Recent studies have demonstrated that the in vitroton (Chen et al., 1997; Ingber, 2003; Tan et al., 2003).
Given the density of the meshwork of crosslinked colla- culture of normal cells within a 3D matrix exerts profound
effects on intracellular signaling cascades, cytoskeletalgen and fibrin that surrounds embedded cells (Figure
6C), cell spreading in response to serum-derived growth organization, and gene expression (Cukierman et al.,
2001, 2002; Walpita and Hay, 2002). Less is known aboutfactors might be predicted to require matrix proteolysis.
Hence, changes in cell geometry were monitored in 3D the behavior of cancer cells under 3D growth conditions,
but we reasoned that the factors regulating the prean-matrices in the absence or presence of MT1-MMP pro-
teolytic activity. As shown in Figure 6D, while MT1- giogenic proliferative activity of tumor cells in situ would
be more accurately recapitulated if cells were sus-MMP-expressing SCC-1 cells readily stretch within 3D
collagen or fibrin gels as well as intact skin, inhibiting pended within a dense, structurally ordered matrix of
crosslinked, type I collagen fibrils. Indeed, under 3DMT1-MMP activity with TIMP-2 traps cells in a compact,
spherical configuration. Confocal images of phalloidin- growth conditions, MMP inhibitors were able to sup-
press tumor cell proliferation in vitro in a fashion similarstained SCC-1 cells embedded in 3D collagen or fibrin
matrices reveals the organization of a centrally located to that described in vivo (Hidalgo and Eckhardt, 2001;
Coussens et al., 2002). Thus, while MMPs were not re-network of stress fibers in stretched cells as compared
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Figure 6. MT1-MMP Promotes Tumor Cell Shape Change and Proliferation in 3D Matrices
(A) Control or MT1-MMP-transfected SCC-1 cells were cultured in 3D fibrin gels for 8 days in the absence or presence of TIMP-2 (5 g/ml).
(B) Proliferative responses of control and MT1-MMP-transfected SCC-1 or MCF-7 cells were determined in 3D fibrin after 8 days in culture
in the absence or presence of TIMP-2 (5 g/ml). Top chart shows total cell numbers expressed as the mean  1 SEM, while the bottom chart
shows the percentage of PCNA-positive cells.
(C) Scanning electron micrographs illustrate (from left to right) the density of the collagen and fibrin matrices (scale bar equals 10 m) relative
to a single cell (on fibrin) or a freeze-fractured multicellular cyst from a MT1-MMP-transfected MDCK culture in collagen (scale bar equals
100 m).
(D) Fluorescent images were obtained of MT1-MMP-expressing SCC-1 cells embedded in 3D collagen gels, fibrin gels, or live skin cultured
for 2 days in the absence or presence of TIMP-2.
(E) Confocal sections of phalloidin-stained MT1-MMP-transfected SCC-1 cells in 3D collagen and fibrin, or control and MT1-MMP-transfected
MCF-7 cells in 3D collagen. Images were collected after 2 days in culture in the absence or presence of TIMP-2 (5 g/ml).
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quired to support the proliferative response of tumor dependent proteolysis allowed tumor cells to escape
from growth regulatory structural constraints and to en-cells seeded atop a 3D collagen gel, a role for MMPs
was unmasked when proliferation proceeded within the gage the necessary cell cycle machinery to drive an
accelerated proliferative response. Tumor cell growthconfines of an organized collagen matrix.
Tumor tissues generate a complex mix of MMPs in was not completely inhibited when pericellular proteoly-
sis was blocked, but the 3D gels used in our studies arevitro and in vivo (Liotta and Kohn, 2001; Brinckerhoff
and Matrisian, 2002; Egeblad and Werb, 2002). As such, less dense and less heavily crosslinked than the ECM
barriers encountered in vivo, thus presumably allowingthe broad spectrum effects of metalloproteinase inhibi-
tors preclude attempts to identify unequivocally in- for shape changes mediated by the mechanical distor-
tion of the surrounding gels. Recent studies havedividual target proteinases. Consequently, we initially
screened a series of MMPs known to be upregulated in stressed the role of the CDK complex inhibitor, p27kip1,
in regulating the proliferative responses of cells culturedcancer tissue for their ability to confer recipient cells
with a 3D-specific growth advantage. However, among atop type I collagen-coated surfaces (Koyama et al.,
1996; Henriet et al., 2000). Similar to these reports, p27kip1the MMPs tested, only MT1-MMP conferred both non-
tumorigenic and tumorigenic cell lines with a 3D ECM- levels were elevated when tumor cells were cultured
under 2D growth conditions in our system. However,specific growth advantage. Furthermore, similar to
cancer cells growing in vivo, the accelerated growth of upon shifting the cells to the 3D growth environment,
p27kip1 levels decreased in both control and MT1-MMP-MT1-MMP-transfected cells was driven almost entirely
by effects on proliferation rather than changes in apo- transfected SCC-1 cells and equivalent amounts of
p27kip1 were detected within the CDK4/cyclin D3 com-ptotic rates (Chambers et al., 2002).
With the identification of MT1-MMP as a growth pro- plexes (unpublished observation). Thus, under the more
physiological conditions of 3D growth, p27kip1 disassoci-moter, we next focused on the identification of potential
target substrates. Recently, the number of MMP sub- ation from CDK complexes may not represent a general
means of cell cycle control in MT-MMP-expressing cells.strates has expanded to include non-ECM targets such
as growth factors, proteinase inhibitors, growth factor Of the major collagenolytic MMPs expressed by tumor
cells (i.e., MMP-1, MMP-13, MMP-2, and MT1-MMP;receptors, and chemokines (Coussens et al., 2002;
Egeblad and Werb, 2002). Nonetheless, MT1-MMP- Brinckerhoff and Matrisian, 2002; Egeblad and Werb,
2002), only MT1-MMP conferred recipient cells with adependent growth was strictly dependent on the hydro-
lysis of the surrounding type I collagen matrix. Native 3D growth advantage. As such, it is tempting to specu-
late that this MMP alone plays a preeminent role incollagen is a ligand for 1 integrins, which could have
exerted transdominant effects on the cell cycle (Eckes regulating cancer cell proliferation. However, we have
recently reported that another membrane-anchoredet al., 2000), but we reasoned that the 3D collagen gel
might alternatively prevent the changes in cell geometry MMP, MT2-MMP, can also arm recipient cells with colla-
gen-degradative activity (Hotary et al., 2000). Similarly,necessary to drive proliferative responses (Chen et al.,
1997; Ingber, 2003; Tan et al., 2003). Recent studies MT1-MMP, MT2-MMP, and MT3-MMP can each medi-
ate fibrinolysis (Hotary et al., 2002). Further studies indi-have demonstrated that cell growth under 2D conditions
not only requires cell attachment, but also spreading, cate that MT2-MMP can similarly enhance the prolifera-
tive activity of cells embedded in type I collagen or fibrintraction, and the consequent rearrangement of the actin
cytoskeleton (Ingber, 2003). By decorating nonadhesive gels while the growth-enhancing effects of MT3-MMP
are confined to fibrin gels alone (unpublished observa-surfaces with small islands of integrin ligands, cell
spreading is restricted and adherent cells are unable to tion). As MT1-MMP, MT2-MMP, and/or MT3-MMP are
expressed in a wide variety of tumor tissues in vivo,exert contractile forces, generate stress fibers, or mount
a proliferative response (Chen et al., 1997; Tan et al., either in the cancer cell itself or the surrounding stroma
(Liotta and Kohn, 2001; Coussens et al., 2002; Egeblad2003). While these artificial constructs likely recapitulate
the early growth of tumor cells confined to the surface of and Werb, 2002), we posit that the 3D growth of neoplas-
tic and accessory cell populations are regulated by MT-the basement membrane, the dense network of fibrillar
collagen presents the embedded tumor cells with a more MMP family members. This conclusion would appear to
contradict recent studies documenting the inability ofrelevant shape change-restricted environment encoun-
tered by invading cancer cells. As such, other physiolog- synthetic MMP inhibitors to effectively suppress some,
but not all, types of tumor growth in vivo (Hidalgo andically relevant fibrillar matrices that are sensitive to MT1-
MMP-dependent proteolysis were predicted to similarly Eckhardt, 2001; Coussens et al., 2002). However, in con-
trast to TIMP-2, synthetic inhibitors can affect membersaffect cell geometry and growth.
Fibrin, the insoluble product of fibrinogen, is depos- of the adamlysin family, whose role in tumor growth and
progression remains the subject of speculation (Hidalgoited around growing tumor cells in vivo, where it is cross-
linked by transglutaminases to form a dense matrix (Hir- and Eckhardt, 2001; Coussens et al., 2002). Given the
almost uniform ability of TIMP-2 to block tumor cellaoka et al., 1998; Hotary et al., 2002). Though fibrin binds
to tumor cells via integrins distinct from those used to growth in vivo (e.g., Montgomery et al., 1994; Brand et
al., 2000; Coussens et al., 2002), the primary actions ofbind to type I collagen (Feng et al., 1999), the crosslinked
fibrils are likewise sensitive to MT1-MMP-dependent the endogenous antiproteinase appear most consistent
with its ability to target growth-promoting MT-MMPs.pericellular proteolysis (Hiraoka et al., 1998). Indeed,
both crosslinked fibrin and collagen potently suppressed Recently, a new model of tumor progression has been
forwarded wherein a subset of mutant alleles acquired3D shape changes, actin cytoskeleton rearrangements,
and cell growth when MT1-MMP-dependent proteolysis early in the neoplastic process are predicted to not only
confer cells with a replicative advantage at the primarywas blocked. Thus, in either 3D matrix, MT1-MMP-
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culture medium and 5  104 cells added to individual wells of 12-site, but also drive the later-onset metastatic process
well tissue culture dishes.(Bernards and Weinberg, 2002). Interestingly, the ability
Cell number in 3D cultures was determined by hemacytometryof MT1-MMP to confer recipient cells with a 3D growth
after dissolving gels in 2 mg/ml bacterial collagenase (Worthington).
advantage complements precisely its ability to arm cells In agar, multicellular (
10 cells) colonies were counted in 10 ran-
with the ability to breach connective tissue barriers (Hir- domly selected microscopic fields. Cell number and colony counts
are expressed as the mean  1 SEM for triplicate cultures.aoka et al., 1998; Hotary et al., 2000, 2002). Hence, we
propose that mutant alleles that regulate MT1-MMP ex-
Cell Labeling, Immunofluorescence,pression (e.g., the -catenin/Tcf4 complex; Takahashi
and Proliferation/Apoptosis Assayset al., 2002) could allow tumor cells to move from planar
For fluorescent cell labeling experiments, cells were labeled withgrowth environments into the underlying 3D matrix
DiI or DiO (Molecular Probes). To create bicultures, 2.5 104 labeled
where the invading cancer cell would use the proteinase cells were mixed with collagen as above and the slurry gelled with
to defeat growth regulatory checkpoints. As MT1-MMP the culture dish angled at approximately 30	. Cells (2.5  104) from
a second labeled (or unlabeled) population were embedded in colla-also imbues cancer cells with the ability to intravasate,
gen, and prior to gelling, layered over the first matrix (see Figure 5).extravasate (unpublished observation), and regulate a
Cultures were fixed in 4% paraformaldehyde, DAPI-stained, andneovascular response (Deryugina et al., 2002; Sounni
cells at the interface of the two collagen layers examined.et al., 2002), membrane-anchored metalloproteinases
Immunofluorescence was performed on frozen sections that were
highlight the ability of early onset gene products to exert fixed in 1% paraformaldehyde, incubated overnight at 4	C with
unexpectedly diverse effects on tumor cell phenotype. monoclonal antibody HUI77 (100 g/ml; gift of Cell-Matrix, Inc., a
subsidiary of CancerVax Corp.) to detect denatured collagen, and
incubated with FITC-conjugated secondary antibody (1:400). BrdUExperimental Procedures
incorporation was assayed following a 60 min pulse with 10 M
BrdU in 3D cultures on day 8 (Henriet et al., 2000). ProliferativeCell Lines
indices in tumor tissue excised from nude mice or fibrin gel culturesMDCK, HT-1080, Panc-1, MCF-7 (all from ATCC), and the squamous
were determined by staining sections for proliferating cell nuclearcell carcinoma cell line, UM-SCC-1 (T. Carey, University of Michi-
antigen (PCNA). Apoptosis was assessed in 3D cultures and in tumorgan), were maintained in DMEM with 10% fetal bovine serum (FBS;
sections using a TUNEL assay kit (Fluorescein Direct Apoptag; In-Hyclone), 2 mM L-glutamine, penicillin (100 U/ml), and streptomycin
tergen).(100 g/ml). Stably transfected cell lines were selected and main-
To assess cell shape changes in 3D collagen or fibrin, cells weretained in geneticin (Life Technologies).
fixed in 4% paraformaldehyde after 2 days in cultures permeabilized
with 0.5% Triton X-100, labeled overnight with Texas red-conjugatedExpression Vectors and Transfections
phalloidin (1:100 in PBS; Molecular Probes), and postfixed in 4%Expression vectors, isolation of stable cell clones, and character-
paraformaldehyde. Confocal images were collected with an Ul-ization of cell lines overexpressing MMPs-1, 2, 3, 7, 9, 11, 13,
traview LCI Confocal Imaging system (Perkin Elmer). For skin cul-MT1-MMP, transmembrane-deleted MT1-MMP (MT1-MMP), cata-
tures, patches of live skin (10–15 mm2) were removed from nudelytically inactive MT1-MMP (MT1-MMP Glu240 → Ala), and cytosolic
mice and approximately 300 DiI-labeled SCC-1 cells (control or MT1-tail-truncated MT1-MMP (MT1-MMPct) have been described (Hotary
MMP-transfected) injected into the dermis through a 30-gauge nee-et al., 2000; Yana and Weiss, 2000). MMP-1RXKR, MMP-2RXKR, and
dle. The skin was immersed in culture medium with or withoutMMP-13RXKR constructs were generated using a sequential PCR
TIMP-2 (10 g/ml) and digital images of labeled cells captured aftermethod (Pei and Weiss, 1995) to insert in-frame a 10 amino acid
2 days in culture.sequence from MMP-11 (Asp87-Phe98) into the coding sequence
of MMP-1 (between Gln99 and Phe100), MMP-2 (between Asn109
Transmission and Scanning Electron Microscopyand Tyr110), and MMP-13 (between Glu103 and Tyr104). Control
Three-dimensional collagen and fibrin gel cultures were preparedcell lines were generated by transfecting cells with the empty vector
for transmission (TEM) and scanning (SEM) electron microscopy as(pCR3.1 Uni; Invitrogen). Results shown are representative of at
described previously (Hotary et al., 2002). For freeze-fracture SEM,least three stable clones.
gels were immersed in liquid N2 and fractured.
2D/3D Culture Conditions and Cell Growth Assays
Western Blots and ZymographyType I collagen was prepared from the tails or skin of rats or mice
MMP protein expression was assessed by Western blotting or zy-[wild-type or homozygous (r/r) Col1a1tmlJae] at a final concentration
mography (Yana and Weiss, 2000). Following transfer, membranesof 2.7 mg/ml in 0.2% acetic acid as described (Hotary et al., 2000).
were probed with anti-MMP-1, anti-MMP-13, or anti MT1-MMP rab-Fibrin gels were prepared by mixing plasminogen-free fibrinogen
bit polyclonal antisera (Hotary et al., 2002) and incubated with HRP-(6 mg/ml; Calbiochem) with human thrombin (4 U/ml; Sigma-Aldrich)
conjugated anti-rabbit IgG secondary antibody. Protein bands werecontaining 200 g/ml aprotinin (Hiraoka et al., 1998). For 2D sub-
visualized using ECL (Pierce Chemical Co.).strata, collagen was mixed on ice with 10MEM (Life Technologies)
and 0.34 N NaOH in an 8:1:1 ratio. For 3D cultures, 5  104 cells
Cyclin-CDK Expression and Kinase Assayswere added to the collagen or fibrin mix prior to gelling. Experiments
To assay cyclin and CDK protein expression, cells were lysed andwere performed in 10% serum before or after MMP-2/MMP-9 deple-
protein (50 g) was separated by SDS-PAGE and transferred totion by gelatin-sepharose affinity chromatography (Amersham Phar-
nitrocellulose membranes (Datta et al., 1996). Blots were probedmacia Biotech; Hiraoka et al., 1998). In selected experiments, the
with antibodies to cyclins A, B, D1, D3, CDK2, CDK4, or CDK6 (Phar-recombinant MMP inhibitors, TIMP-1 and TIMP-2 (endotoxin-free;
mingen or Santa Cruz Biotechnology), incubated with isotype-spe-Fuji Industries), were included at a final concentration of 5 g/ml
cific HRP-conjugated secondary antibody and visualized by ECL.for TIMP-2 and 12.5 g/ml of TIMP-1 (equimolar as determined by
For kinase activity determinations, cell lysates were immunoprecipi-active site titration; Hotary et al., 2002). For collagen/gelatin mix-
tated with anti-cyclin antibodies and incubated with protein A/Gtures, gelatin prepared either by thermal denaturation of type I colla-
sepharose beads (Datta et al., 1996). Immune complexes were as-gen at 60	C or by degrading collagen with recombinant MT1-MMP
sayed with purified GST-Rb protein (Santa Cruz) or H1-histone(Hiraoka et al., 1998) was added to type I collagen and the mixture
(Roche Diagnostic Corporation) as substrate (Datta et al., 1996).gelled as described above. Monoclonal antibodies HU177 (Petitclerc
et al., 1999) or LM609 (Wayner et al., 1991) were used at a final
concentration of 100 g/ml or 20 g/ml, respectively. Tumor Growth in Nude Mice
5 106 SCC-1 cells (control or stable transfectants) were suspendedIn selected experiments, tumor cell growth was assessed in a
soft agar assay. Agar (2.5%; Sigma) was diluted to 0.5% in tissue in DMEM (0.2 ml) and injected subcutaneously into each flank of 5-
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to 6-week-old female nude mice (NU/NU; Charles River). Tumors Hidalgo, M., and Eckhardt, S.G. (2001). Development of matrix met-
alloproteinase inhibitors in cancer therapy. J. Natl. Cancer Inst. 93,were allowed to develop for two weeks, at which time the mice were
sacrificed and photographed. Tumors were excised for mass and 178–193.
volume measurements. Hiraoka, N., Allen, E., Apel, I.J., Gyetko, M.R., and Weiss, S.J. (1998).
Matrix metalloproteinases regulate neovascularization by acting as
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